2. Protein Tyrosine Kinase/RTK
  3. FGFR
  4. Bemarituzumab

Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 1952272-74-0

Tamaño Precio Stock Cantidad
Muestra gratis (100 μg)   Solicite ahora  
1 mg En stock
5 mg En stock
10 mg En stock
50 mg   Obtener un presupuesto  
100 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Bemarituzumab Related Antibodies

Top Publications Citing Use of Products

  • Actividad biológica

  • Pureza y Documentación

  • Referencias

  • Revisión del cliente

Descripciòn

Bemarituzumab is a humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has antitumor activity against gastric and breast cancer[1][2].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

FGFR2/CD332
In Vitro

Bemarituzumab (0.001-100 μg/mL, 30 min) inhibits FGF7-induced FGFR2 phosphorylation and cell proliferation in a concentration-dependent manner in the SNU-16 human gastric cancer cells, reaching a maximal value at ≥6.25 μg/mL[2].
Bemarituzumab exhibits immune cell-mediated killing of tumor cells overexpressing FGFR2b[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Bemarituzumab Related Antibodies
In Vivo

Bemarituzumab (1-5 mg/kg; i.v.; twice a week) inhibits tumor growth in a dose-dependent manner and causes tumor regression in some mice in the xenograft mouse model of OCUM-2M human gastric cancer cells[2].
Bemarituzumab (5 mg/kg; i.p.; twice a week) combined with 5-fluorouracil (HY-90006) and Oxaliplatin (HY-17371) significantly inhibits tumor growth more than monotherapy and does not increase chemotherapy-related toxicity in the OCUM-2M gastric cancer xenograft model[2].
Bemarituzumab (10 mg/kg; i.p.; biweekly) significantly reduces tumor burden, recruits NK cells, and increases PD-L1-expressing cells and CD3-positive T cells in the syngeneic 4T1 mouse mammary tumor model[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female CB17 SCID mice (7-8 weeks old), xenograft model of OCUM-2M human gastric cancer cells[2]
Dosage: 1 mg/kg, 1.5 mg/kg, 2 mg/kg, 3 mg/kg, 5 mg/kg (in PBS)
Administration: Intravenous injection, twice a week
Result: Inhibited tumor growth in a dose-dependent manner.
Inhibited and regressed tumor growth starting from a dose of 1 mg/kg.
Caused complete tumor regression in 1/15 mice at the 1.5 mg/kg and 2 mg/kg doses, 4/15 mice at the 3 mg/kg dose, and 6/15 mice at the 5 mg/kg dose by day 42.
Animal Model: Tg-ArcSwe transgenic mice (11-14 months old) harboring the APP Arctic mutation[3]
Dosage: 10 mg/kg
Administration: i.p., once weekly, for 4/13 weeks
Result: Achieved brain amyloid-β (Aβ) protofibril and cerebrospinal fluid (CSF) Aβ protofibrils/oligomers reduction.
Ensayo clínico
Gene ID

2263  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Peso molecular

143.86 kDa

No. CAS
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Bemarituzumab]
Envío

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Immobilized FGFR-2 alpha (IIIb) Protein, Human (HEK293, His, HY-P76336) can bind Bemarituzumab. The EC50 for this effect is 5.673 ng/mL.
Pureza y Documentación

Purity: 99.82%

SDS (251 KB)

COA (232 KB) SDS-PAGE (70 KB) SEC-HPLC (121 KB)

Inhibitory Antibodies User Guide (603 KB)
Referencias
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Bemarituzumab Related Classifications

  • Calculadora de molaridad

  • Calculadora de dilución

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Bemarituzumab1952272-74-0FGFRFibroblast growth factor receptorfirst-in-classhumanized IgG1 monoclonal antibodanticancermammary tumorInhibitorinhibitorinhibit

Productos vistos recientemente:

Consulta en línea

Your information is safe with us. * Required Fields.

Nombre del producto

  

Requested Quantity *

Nombre del solicitante *

 

Saludo

Direcciòn del E-mail *

 

Número de teléfono *

Department

 

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

      

Observaciones

Consulta para venta a granel

Inquiry Information

Nombre del producto:
Bemarituzumab
Cat. No.:
HY-P99010
Cantidad:
MCE Japan Authorized Agent:

Revisión del cliente

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Nombre del producto

  

Lot #

Nombre del solicitante *

 

Direcciòn del E-mail *

Número de teléfono

 

Department *

Nombre de la Organizaciòn *

 

Country or Region *

Observaciones

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.